Publications by authors named "Taichiroh Nishikawa"
A 56-year-old male patient with chronic hepatitis C was treated with pegylated interferon (PEG IFN)-α-2b and ribavirin (RBV) for 72 weeks in 2006. The patient achieved an early virological response (EVR); however, hepatitis C relapsed 12 weeks after discontinuation of PEG IFN and RBV. In 2012, the patient was treated with a PEG IFN/RBV/telaprevir combination therapy.
View Article and Find Full Text PDFArticle Synopsis
- Statins, like rosuvastatin, may help treat steatohepatitis, a liver condition caused by high-fat and high-cholesterol diets, by reducing cholesterol levels and associated liver damage.
- In a rat study, rosuvastatin significantly decreased liver fat content, inflammation markers, and fibrotic changes compared to control diets, indicating potential therapeutic effects.
- The research suggests that these benefits occur through improved oxidative processes in the liver, highlighting the broader protective roles of statins beyond just lowering cholesterol.
Aim: Our aim was to clarify the significance of expression levels and post-transcriptional splicing patterns of survivin during multistep hepatocarcinogenesis and tumor progression.
Methods: Using immunohistochemistry, we first elucidated the expression of survivin protein in tissues of hepatocellular carcinoma (HCC) and the adjacent non-cancerous tissues. Furthermore, we investigated survivin gene expression patterns in these tissues.